Antibody Start-Ups: Riding the Big Pharma Acquisition Wave
This article was originally published in Start Up
Executive Summary
It's a good time to be an antibody company. As almost all the Big Pharma fall over each other to grab whatever antibody assets they can, investors backing still-independent firms are rubbing their hands in glee. One of the companies we profile this month claims it has found a novel route around the one major drawback to antibody development--the dreaded IP blackout. But whatever their trump card-whether they're improving existing antibodies, like Anaptys and 4-antibody, or, like f-star, creating antibody fragments, interest from strategic partners is guaranteed.
You may also be interested in...
The A-List: 2007's Trend Shaping Series A Financings
In 2007, what did Series A venture investments reveal about the state of the health care industry? It was very healthy, thank you. There were quite a few deals to choose from, and numbers demonstrated continued growth in diagnostics fundraising, a resurgence in vaccines, and evidence of pharma's interest in proof-of-concept projects and large-molecule platforms. Medical device investors, meanwhile, remain enamored with concept companies seeking to blend electronics-such as neurostimulation or miniature sensors-with devices.
The A-List: 2007's Trend Shaping Series A Financings
In 2007, what did Series A venture investments reveal about the state of the health care industry? It was very healthy, thank you. There were quite a few deals to choose from, and numbers demonstrated continued growth in diagnostics fundraising, a resurgence in vaccines, and evidence of pharma's interest in proof-of-concept projects and large-molecule platforms. Medical device investors, meanwhile, remain enamored with concept companies seeking to blend electronics-such as neurostimulation or miniature sensors-with devices.
Start-Up Previews (11/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibody Start-Ups," features profiles of 4-Antibody, Anaptys Biosciences and f-star. Plus these Start-Ups Across Health Care: Actuality Medical, INBONE Technologies, Interrad Medical and Tethys BioScience.